Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE’24 Phase 2 MaGic trial of DNTH103 in generalized ...
Substance use disorders are notoriously difficult to treat, as it is challenging to intervene in a drugs’ effect on the brain’s reward pathway without interfering with the pathway’s normal function.